Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal 2026 results covered year ended June 30, 2026.
ARROWHEAD PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal 2026 results covered year ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing management’s financial commentary
- Results furnished under Regulation FD and not treated as filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Fiscal Q3 revenue $75.3M vs $27.8M, while net loss attributable to Arrowhead widened to $194.3M from $175.2M
- REDEMPLO prescription volume roughly doubled, with more than 400 prescribing practitioners and improving major-payer coverage
- SHASTA-3 and SHASTA-4 delivered 79% and 81% median triglyceride reductions, plus 78% fewer acute pancreatitis events versus placebo
- FDA priority review voucher targets plozasiran’s sNDA before year-end 2026, potentially reducing review to 6 months from 10 months
- Madrigal license adds $25M upfront, up to $975M milestones, and tiered royalties for ARO-PNPLA3; total cash resources reached $1.57B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARROWHEAD PHARMACEUTICALS, INC. 8-K filings
Get the next ARWR 8-K as it lands
Follow ARWR for push alerts, or ask the research agent what this filing means.